1.De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, Daar S, et al. An ICET-A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report. Acta Bio Medica Atenei Parmensis. 2018;88(4):435-44.
2.Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia. Endokrynologia Polska. 2012;63(4):260-3.
3.Gombar S, Parihar K, Choudhary M. Comparative study of serum ferritin and vitamin D in thalassemia patients with healthy controls. International Journal of Research in Medical Sciences. 2018;6(2):693-5.
4.Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, et al. Management of hypoparathyroidism: summary statement and guidelines. The Journal of Clinical Endocrinology & Metabolism. 2016;101(6):2273-83.
5.Abate EG, Clarke BL. Review of hypoparathyroidism. Frontiers in endocrinology. 2017;7:172.
6.Sneddon WB, Ruiz GW, Gallo LI, Xiao K, Zhang Q, Rbaibi Y, et al. Convergent signaling pathways regulate parathyroid hormone and fibroblast growth factor-23 action on NPT2A-mediated phosphate transport. Journal of Biological Chemistry. 2016:jbc. M116. 744052.
7.Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. The Journal of clinical investigation. 2004;113(4):561-8.
8.Yamashita T, Konishi M, Miyake A, Inui K-i, Itoh N. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. Journal of Biological Chemistry. 2002;277(31):28265-70.
9.Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and biophysical research communications. 2000;277(2):494-8.
10.Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Experimental cell research. 2012;318(9):1040-8.
11.Ranch D, Zhang MY, Portale AA, Perwad F. Fibroblast growth factor 23 regulates renal 1, 25‐dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. Journal of bone and mineral research. 2011;26(8):1883-90.
12.Prié D, Friedlander G. Reciprocal control of 1, 25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clinical Journal of the American Society of Nephrology. 2010:CJN. 02680310.
13.Juppner H, Abou-Samra A-B, Freeman M, Kong XF, Schipani E, Richards J, et al. AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991;254(5034):1024-6.
14.Guo J, Chung U-I, Kondo H, Bringhurst FR, Kronenberg HM. The PTH/PTHrP receptor can delay chondrocyte hypertrophy in vivo without activating phospholipase C. Developmental cell. 2002;3(2):183-94.
15.Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. The Journal of Clinical Endocrinology & Metabolism. 2009;94(7):2332-7.
16.Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814-6.
17.Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of Bone and Mineral Research. 2013;28(8):1793-803.
18.Deger SM, Erten Y, Pasaoglu OT, Derici UB, Reis KA, Onec K, et al. The effects of iron on FGF23-mediated Ca–P metabolism in CKD patients. Clinical and experimental nephrology. 2013;17(3):416-23.
- Pirinççioğlu1 AG, Söker DG. Parathyroid functions in thalassemia major patients. Ann Clin Endocrinol Metab 2017;1:15-9.
20.Pawlotsky Y, Le Dantec P, Moirand R, Guggenbuhl P, Jouanolle AM, Catheline M, et al. Elevated parathyroid hormone 44–68 and osteoarticular changes in patients with genetic hemochromatosis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1999;42(4):799-806.
21.Gutteridge JM, Halliwell B. 1 Iron toxicity and oxygen radicals. Bailliere's clinical haematology. 1989;2(2):195-256.
22.Modi AS, Poornima R, DS JM. SERUM CALCIUM AND PHOSPHATE LEVELS IN PATIENTS WITH β-THALASSEMIA MAJOR. therapy.2:9.
23.Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini G, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone. 2006;38(6):888-92.
24.Wood JC, Claster S, Carson S, Menteer J, Hofstra T, Khanna R, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. British journal of haematology. 2008;141(6):891-4.
25.Dandona P, Menon RK, Houlder S, Thomas M, Hoffbrand AV, Flynn DM. Serum 1, 25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major. Archives of disease in childhood. 1987 May 1;62(5):474-7.
26.Charoenphandhu N, Kraidith K, Teerapornpuntakit J, Thongchote K, Khuituan P, Svasti S, Krishnamra N. 1, 25‐Dihydroxyvitamin D3‐induced intestinal calcium transport is impaired in β‐globin knockout thalassemic mice. Cell biochemistry and function. 2013 Dec;31(8):685-91.
27.Tanaka Y, DeLuca H. Role of 1, 25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proceedings of the National Academy of Sciences. 1974;71(4):1040-4.
28.Saito H, Maeda A, Ohtomo S-i, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1α, 25-dihydroxyvitamin D3 and phosphorus in vivo. Journal of Biological Chemistry. 2005;280(4):2543-9.
29.Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36(6):971-7.
30.Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. American Journal of Physiology-Renal Physiology. 2010;299(4):F882-F9.
31.López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, De Oca AM, Pineda C, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney international. 2011;80(5):475-82.
- Tangngam H, Mahachoklertwattana P, Poomthavorn P, Chuansumrit A, Sirachainan N, Chailurkit LO, Khlairit P. Under-recognized hypoparathyroidism in thalassemia. Journal of clinical research in pediatric endocrinology. 2018 Dec;10(4):324.
33.Clarke BL. FGF23 regulation of phosphorus homeostasis is dependent on PTH. Oxford University Press; 2011.
34.Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, et al. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation. Endocrine journal. 2007;54(3):465-70.